<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257032</url>
  </required_header>
  <id_info>
    <org_study_id>1405-0015</org_study_id>
    <secondary_id>2019-004245-33</secondary_id>
    <nct_id>NCT04257032</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood</brief_title>
  <official_title>Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this trial are to investigate the relative bioavailabilities of&#xD;
      rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and&#xD;
      together with BI 1323495 (Test 1, Test 2) following oral administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Actual">September 23, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of Rosuvastatin in plasma (Cmax)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of Dabigatran in plasma (Cmax)</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference 1 (R1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 1 (T1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2 (R2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2 (T2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Reference 1 (R1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin + BI 1323495</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Test 1 (T1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Reference 2 (R2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate + BI 1323495</intervention_name>
    <description>Capsule and tablets</description>
    <arm_group_label>Test 2 (T2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (BP, PR),&#xD;
             12-lead ECG, and clinical laboratory tests&#xD;
&#xD;
          2. Age of 18 to 55 years (inclusive)&#xD;
&#xD;
          3. BMI of 18.5 to 29.9 kg/m2 (inclusive)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          5. Subjects genotyped as Uridine 5'-diphospho-Glucuronosyltransferase-2B17 (UGT2B17)&#xD;
             extensive metabolisers, i.e. carrying at least one functional allele of UGT2B17 gene&#xD;
             (*1/*1 or *1/*2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 45 to 90 bpm&#xD;
&#xD;
          3. Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance (including positive or missing faecal occult blood test in Part&#xD;
             2)&#xD;
&#xD;
          4. Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological, or hormonal disorders&#xD;
&#xD;
          6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          7. Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          8. History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          9. Chronic or relevant acute infections&#xD;
&#xD;
         10. History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medications or their excipients)&#xD;
&#xD;
         11. Use of drugs within 30 days of planned administration of trial medication that might&#xD;
             reasonably influence the results of the trial or compromise the subject's safety by&#xD;
             participation in the trial (e. g. use of any drug that could reasonably inhibit&#xD;
             platelet aggregation or coagulation, concomitant treatment with systemic cyclosporine,&#xD;
             ketoconazole, itraconazole and dronedarone, use of fibrates or drugs that cause QT/QTc&#xD;
             interval prolongation (QTc: QT interval corrected for heart rate using the method of&#xD;
             Fridericia (QTcF) or Bazett (QTcB))&#xD;
&#xD;
         12. Intake of an investigational drug in another clinical trial within 60 days of planned&#xD;
             administration of investigational drug in the current trial, or concurrent&#xD;
             participation in another clinical trial in which investigational drug is administered&#xD;
&#xD;
         13. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
         14. Inability to refrain from smoking on specified trial days&#xD;
&#xD;
         15. Alcohol abuse (consumption of more than 24 g per day)&#xD;
&#xD;
         16. Drug abuse or positive drug screening&#xD;
&#xD;
         17. Blood donation of more than 100 mL within 30 days of planned administration of trial&#xD;
             medication or intended blood donation during the trial&#xD;
&#xD;
         18. Intention to perform excessive physical activities within one week prior to the&#xD;
             administration of trial medication or during the trial&#xD;
&#xD;
         19. Inability to comply with the dietary regimen of the trial site&#xD;
&#xD;
         20. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are&#xD;
             repeatedly greater than 450 ms) or any other relevant ECG finding at screening&#xD;
&#xD;
         21. A history of additional risk factors for Torsade de Pointes (such as heart failure,&#xD;
             hypokalaemia, or family history of Long QT Syndrome)&#xD;
&#xD;
         22. Subject is assessed as unsuitable for inclusion by the investigator, for instance,&#xD;
             because the subject is not considered able to understand and comply with study&#xD;
             requirements, or has a condition that would not allow safe participation in the study&#xD;
&#xD;
         23. Male subjects with women of childbearing potential (WOCBP) partner who are unwilling&#xD;
             to use male contraception (condom or sexual abstinence) from time point of&#xD;
             administration of trial medication until 30 days thereafter. Sperm donation is not&#xD;
             allowed from the time point of drug administration until 30 days thereafter.&#xD;
&#xD;
         24. Active clinically relevant bleeding or subjects who in the investigator's judgement&#xD;
             are perceived as having an increased risk of bleeding, for example because of blood&#xD;
             coagulation disorders, current or recent gastrointestinal ulceration, presence of&#xD;
             malignant neoplasms, recent brain or spinal injury, recent brain/spinal/ophthalmic&#xD;
             surgery, recent intracranial hemorrhage, known or suspected oesophageal varices,&#xD;
             arteriovenous malformations, vascular aneurysms, major intraspinal or intracerebral&#xD;
             vascular abnormalities&#xD;
&#xD;
         25. For Part 1 only: known myopathy, personal or family history of hereditary muscular&#xD;
             disorders, or history of muscular toxicity with statins or fibrate; Asian ancestry;&#xD;
             hypothyroidism&#xD;
&#xD;
         26. Subjects with any other condition that would preclude administration of rosuvastatin&#xD;
             or dabigatran (i.e. contraindicated as per SmPC), such as active liver disease&#xD;
             including elevations of serum transaminases exceeding 2 times the upper limit of&#xD;
             normal, moderate or severe renal impairment (creatinine clearance &lt; 60 ml/min based on&#xD;
             estimated glomerular filtration rate (GFR) according to Chronic Kidney Disease&#xD;
             Epidemiology Collaboration (CKD-EPI) formula), prosthetic heart valves requiring&#xD;
             anticoagulant treatment&#xD;
&#xD;
         27. During COVID-19 pandemic: laboratory test indicative of an ongoing SARS-CoV-2&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanpharmakologisches Zentrum Biberach</name>
      <address>
        <city>Biberach</city>
        <zip>88397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

